Esperion Therapeutics Inc. [NASDAQ: ESPR] traded at a low on 03/06/23, posting a -19.95 loss after which it closed the day’ session at $5.07. The company report on March 4, 2023 that Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin.
– NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial Infarction by 23% (P=0.002) and Coronary Revascularization by 19% (P=0.001) –.
The results of the trading session contributed to over 15136393 shares changing hands. Over the past one week, the price volatility of Esperion Therapeutics Inc. stands at 9.14% while the volatility over the past one month is 6.53%.
The market cap for ESPR stock reached $389.81 million, with 73.56 million shares outstanding and 73.15 million shares in the current float. Compared to the average trading volume of 2.28M shares, ESPR reached a trading volume of 15136393 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Esperion Therapeutics Inc. [ESPR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $11.59 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 27, 2023. The new note on the price target was released on February 24, 2023, representing the official price target for Esperion Therapeutics Inc. stock. Previously, the target price had yet another raise to $9, while Morgan Stanley analysts kept a Equal-Weight rating on ESPR stock. On August 03, 2022, analysts decreased their price target for ESPR shares from 7 to 6.
The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.47, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 5.16.
How has ESPR stock performed recently?
Esperion Therapeutics Inc. [ESPR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.61. With this latest performance, ESPR shares dropped by -14.27% in over the last four-week period, additionally sinking by -34.01% over the last 6 months – not to mention a rise of 21.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 34.81, with the RSI for the last a single of trading hit 30.71, and the three-weeks RSI is set at 37.60 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 6.23, while it was recorded at 5.99 for the last single week of trading, and 6.67 for the last 200 days.
Esperion Therapeutics Inc. [ESPR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -237.83 and a Gross Margin at +63.61. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -309.58.
Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 2.70.
Earnings analysis for Esperion Therapeutics Inc. [ESPR]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.
Insider trade positions for Esperion Therapeutics Inc. [ESPR]
There are presently around $374 million, or 87.80% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS INC with ownership of 6,848,378, which is approximately -8.236% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 5,509,187 shares of the stock with an approximate value of $27.96 million in ESPR stocks shares; and MEDITOR GROUP LTD, currently with $22.68 million in ESPR stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Esperion Therapeutics Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 105 institutional holders increased their position in Esperion Therapeutics Inc. [NASDAQ:ESPR] by around 21,301,391 shares. Additionally, 66 investors decreased positions by around 10,935,453 shares, while 23 investors held positions by with 41,483,368 shares. The mentioned changes placed institutional holdings at 73,720,212 shares, according to the latest SEC report filing. ESPR stock had 46 new institutional investments in for a total of 10,176,975 shares, while 26 institutional investors sold positions of 4,808,184 shares during the same period.